BioVie's Core Patent Covering BIV201 as Treatment for Ascites Allowed by US Patent Office

BEVERLY, MA--(Marketwired - March 15, 2017) - BioVie Inc. (OTCQB: BIVI), a development-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, is pleased to announce the appointment of Julie G. Anderson as an independent member of t...

BEVERLY, MA--(Marketwired - March 06, 2017) - BioVie Inc. (OTCQB: BIVI), a development-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, announced today that its stock has commenced trading on the OTCQB market after successful...